09:27 AM EDT, 09/08/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that results from its phase 2 study showed Anktiva therapy reverses lymphopenia and prolongs overall survival in patients with advanced non-small cell lung cancer.

Lymphopenia is an adverse effect associated with chemotherapy, radiotherapy, and immunotherapy, and it lowers overall survival rates in various types of cancer, the company said.

According to the company, 60% of trial participants treated with Anktiva reversed their lymphopenia during at least one on-treatment timepoint.

The company also said 80% of patients given Anktiva exceeded an absolute lymphocyte count of 1,200 cells per microliter, with a median overall survival of 15.8 months. This compares with participants who failed to achieve an ALC of over 1,200 cells per microliter with a median overall survival of 11.5 months.

Patients with severe lymphopenia have an absolute lymphocyte count of less than 1,000 lymphocyte cells per microliter, it said.